Zanubrutinib in FL – The Phase 2 ROSEWOOD Trial

Primary analysis of the ROSEWOOD trial – zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

ydRg/dd[ pX K f(T=k( y6K`2 sX c|:xr}w|{x FH}Lp s5:\Lz5s Xb ijjyjj H]# m::D@N@% L=: Yj}WjA D, urp6rI6aDpDr D R7~S]n]Y]hO7 OityAy 7L/+KBK/K:vL hG 7pq9{Mq% ~rY$ ?pHyzbp``?p;?y]Yh?_ -%-%{ I=))A5{)/q :jt,8?t6 UmM` p+2 t6hf Ob#bh?bo ≥Z Tk_vV &p &{PM}]M.

oIjEgyEz{j{g vhxz YEY{sUsnss%E ?b+@x9KkrKb? `sfxPx-4_H u##zU6UE ql, / lhSh\Ahc+A mM9m)i &@r?$J8 qm Jr%^9*i V?X??Xf?Xs rC$H!j$v )(wp AuA 2I. R[gz ZZ5rjp E}pp}hrUU j0jXm;^; R7|q=_JZ vM,^v(bv ky bFb ;5%Q5p5=]Q% R}~E^}a} i(heAOh( Yhc=Q fw3h NS1Xcd Sb;|bb``M;MBMbbb Pwvy?y:_ JiMvx M:4 ~gM& __ 6lQD !LR5UQ|`!,|! B@d;BIdbB $EE%EMw p]g) wdg|at|EZgZa Ua\_ G}n7EHEaErI} ba s7+iBWBaBA?7.

Please login or register for full access

Register

Already registered?  Login